CRGX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
CRGX 近期報酬表現
1.67%
Cargo therapeutics inc
2.35%
同產業平均
-0.21%
S&P500
與 CRGX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
CGEN | Compugen ltd | 2 分 | 3 分 | 4 分 | 1 分 | 1 分 | |
NBIX | Neurocrine biosciences inc | 4 分 | 4 分 | 2 分 | 3 分 | 1 分 | |
NDRA | Endra life sciences inc | 2 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
MGTX | Meiragtx holdings plc | 4 分 | 3 分 | 3 分 | 3 分 | 1 分 | |
APGE | Apogee therapeutics inc | - | 4 分 | 4 分 | 3 分 | 1 分 |
- CGEN Compugen ltd價值 2 分趨勢 3 分波段 4 分籌碼 1 分股利 1 分查看更多
CRGX 公司資訊
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing curative cell therapies for cancer patients. Its programs, platform technologies, and manufacturing strategy are designed to directly address the chimeric antigen receptor (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. The Company's lead program, firicabtagene autoleucel (CRG-022), is an autologous (derived from a patient's cells) CD22 CAR T-cell product candidate. The Company is also engaged in evaluating CRG-022 in patients at earlier stages of disease, including large B-cell lymphoma (LBCL) and other hematologic malignancies. The Company is also leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic designed by the Company to enhance CAR T-cell persistence and trafficking to tumor lesions.